When the population you represent, the color you share and the mutations in your genes are not represented during clinical trials, then there is a deliberate imbalance in addressing cancer treatment.

Hence, results from such clinical trials cannot be considered absolute because diversity is absent.

Colon Cancer is killing our black men and women more than our counterpart. In fact, not up to 30 % African Americans are included in clinical trials.

Meanwhile, black men & women are at the greatest risk of dying from colon cancer.

When trial participants are of the same origin and not diverse, research findings to address cancer may be skewed and result in a body of clinical knowledge that is narrow.

This translates to retrogression in cancer research.

We pray that our advocacy change the narrative soon.

Photo source: FDA